Estrella Immunopharma, Inc. (ESLA) Income Statement
ESLA 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsESLA revenue and net income
ESLA growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
ESLA quarterly EPS vs estimates
Estrella Immunopharma beat the analyst EPS estimate in 6 of the last 8 quarters.
ESLA income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Research & development | $10.2M | $6.4M | $4.1M | $10.5M | $1.4M | $457,231 |
| Sales, general & admin | $2.8M | $2.4M | $3.2M | $663,190 | $296,248 | $276,462 |
| Total operating expenses | $13.1M | $8.8M | $7.3M | $11.1M | $1.7M | $733,693 |
| Operating income | −$13.1M | −$8.8M | −$7.3M | −$11.1M | −$1.7M | −$733,693 |
| Income before taxes | −$13.1M | −$8.8M | −$7.3M | −$11.1M | −$1.7M | −$733,693 |
| Income taxes | $838 | $1,688 | — | $80,648 | −$235,136 | −$206,297 |
| Net income | −$13.1M | −$8.8M | −$7.3M | −$11.1M | −$1.7M | −$733,693 |
| EBITDA | −$13.1M | −$8.8M | −$7.3M | −$11.1M | −$1.7M | −$733,693 |
| EPS (diluted) | −$0.35 | −$0.24 | −$1.87 | −$0.25 | −$0.14 | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Research & development | $1.4M | $1.4M | $25,414 | $4.2M | $4.7M | $1.4M | $32,566 | $2.8M | $3.5M | $25,000 | $75,459 | $483,466 |
| Sales, general & admin | $684,015 | $891,789 | $587,785 | $648,507 | $883,727 | $694,110 | $1.0M | $550,737 | $424,447 | $444,530 | $945,165 | $1.4M |
| Total operating expenses | $2.1M | $2.3M | $613,199 | $4.8M | $5.5M | $2.1M | $1.1M | $3.4M | $3.9M | $469,530 | $1.0M | $1.9M |
| Operating income | −$2.1M | −$2.3M | −$613,199 | −$4.8M | −$5.5M | −$2.1M | −$1.1M | −$3.4M | −$3.9M | −$469,530 | −$1.0M | −$1.9M |
| Income before taxes | −$2.3M | −$2.3M | −$613,199 | −$4.8M | −$5.5M | −$2.1M | −$1.1M | −$3.4M | −$3.9M | −$469,530 | −$1.0M | −$1.9M |
| Income taxes | — | — | −$25 | — | $850 | $13 | $63 | $1,625 | $1,625 | $39,586 | −$122,089 | −$41,581 |
| Net income | −$2.3M | −$2.3M | −$613,174 | −$4.8M | −$5.5M | −$2.1M | −$1.1M | −$3.4M | −$4.0M | −$469,530 | −$1.0M | −$1.9M |
| EBITDA | −$2.1M | −$2.3M | −$613,199 | −$4.8M | −$5.5M | −$2.1M | −$1.1M | −$3.4M | −$3.9M | −$469,530 | −$898,539 | −$1.8M |
| EPS (diluted) | −$0.05 | −$0.05 | −$0.01 | −$0.13 | −$0.15 | −$0.06 | −$0.03 | −$0.09 | −$0.11 | −$0.01 | −$0.03 | −$1.78 |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in ESLA's financial statements (latest annual report filed March 18, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
ESLA financial results
Estrella Immunopharma reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $13.1 million. Diluted earnings per share came to −$0.35.
See the ESLA stock overview for the latest quote and news, or the ESLA chart for price history and technical indicators.
ESLA income statement FAQ
Does Estrella Immunopharma have revenue?
Estrella Immunopharma reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Estrella Immunopharma profitable?
No. Estrella Immunopharma reported a net loss of $13.1 million in fiscal 2025.
How much does Estrella Immunopharma spend on research and development?
Estrella Immunopharma spent $10.2 million on research and development in fiscal 2025.
What are Estrella Immunopharma's earnings per share?
Estrella Immunopharma earned $-0.35 per diluted share in fiscal 2025, compared with $-0.24 a year earlier.
When does Estrella Immunopharma's fiscal year end?
Estrella Immunopharma's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 18, 2026.